论文部分内容阅读
Objective:Meta-analysis was performed to evaluate the safety of clopidogrel and tigrel in the treatment of non-ST-segment elevation acute coronary syndrome after intervention. Methods: by searching the databases of cnki, wanfang database, weipu network, bailian and so on, relevant literatures on oral clopidogrel sulfate and tigrel after interventional treatment of non-ST-elevation acute coronary syndrome were collected. Search the required literature according to the inclusion criteria and exclusion criteria. Risk assessment of the included literature was performed on the basis of Cochrane reviews or the Newcastle scale (NOS). Fixed two researchers randomly and the control group, experimental group into literature alone assessed, Use software Review Manager 5.3 analyze aspirin and clopidogrel, aspirin and ticagrelor drug for the safety of the drug after therapy intervention Meta analysis, merge effect value odds ratio (OR) and 95％ confidence interval, inspection heterogeneity and publication bias.Results: a total of 16 articles met the criteria, and 3007 patients were included in the meta-analysis. Compared with the clopidogrel sulfate group, the tigrilol group significantly reduced the incidence of major cardiovascular adverse events after interventional therapy for non-ST-segment elevation acute coronary syndrome(MACE) OR=0.37,95％Cl=(0.280.49) (P<0.00001)、Angina symptoms OR=0.46, 95％Cl= (0.260.81) (P=0.008)、Non-fatal heart infarction OR=0.38, 95％cl = (0.260.81) (P=0.001)、heart failure OR=0.41, 95％cl = (0.180.96) (P=0.04)、cardiac death OR=0.31, 95％cl = (0.150.64) (P=0.002)、target vessel revascularization OR=0.46, 95％cl = (0.210.99) (P=0.05),However, increased respiratory distress OR=4.44, 95％cl = (2.089.45) (P<0.0001)、bleeding events OR=2.06, 95％cl = (1.303.27) (P=0.002)、arrhythmia OR=1.14, 95％cl = (0.851.54) (P=0.39).Conclusion:In the treatment of non-ST-segment elevation acute coronary syndrome after interventional surgery, compared with clopidogrel, Tigliero can reduce the incidence of major cardiovascular adverse events, angina symptoms, non-fatal cardiac infarction, heart failure, cardiogenic death, and target vessel revascularization, However, the incidence of dyspnea, bleeding events and arrhythmias increased.